NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $36.80 -0.66 (-1.76%) As of 11:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harrow Stock (NASDAQ:HROW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harrow alerts:Sign Up Key Stats Today's Range$36.25▼$37.7550-Day Range$30.68▼$46.6552-Week Range$28.54▼$54.85Volume150,382 shsAverage Volume746,681 shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$69.43Consensus RatingModerate Buy Company Overview Harrow Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders. Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations. Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.AI Generated. May Contain Errors. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 83% of companies evaluated by MarketBeat, and ranked 93rd out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingHarrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialHarrow has a consensus price target of $69.43, representing about 84.4% upside from its current price of $37.65.Amount of Analyst CoverageHarrow has only been the subject of 3 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth675.86% Earnings GrowthEarnings for Harrow are expected to grow by 675.86% in the coming year, from $0.29 to $2.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -92.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -92.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 26.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.06% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 12.62, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently decreased by 4.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentHarrow has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Harrow this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Harrow to their MarketBeat watchlist in the last 30 days. Company Ownership4.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Harrow in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $135,720.00 in company stock, which represents 0.0097% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,720.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Stock News HeadlinesHarrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026July 27 at 7:00 AM | globenewswire.comBTIG Research Reiterates Buy Rating for Harrow (NASDAQ:HROW)July 23, 2026 | americanbankingnews.comThe $8,000 Gold Call Every Retirement Saver Needs to Read Right NowGold didn't creep higher—it broke $5,000, a level many analysts thought would hold. Now JPMorgan, the biggest bank on earth, just raised its 2026 gold forecast to $6,300 and laid out a credible path to $8,000 if everyday investors increase their gold allocations even slightly. Most Americans hold less than 1% in gold, and if that number moves even slightly higher, demand collides with limited supply, and prices reprice fast.July 28 at 1:00 AM | Golden Crest Metals (Ad)Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 22, 2026 | americanbankingnews.comSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ...July 20, 2026 | finance.yahoo.comSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026July 20, 2026 | globenewswire.comHarrow Announces ASRS 2026 Presentation of Studies Supporting IHEEZO and BYOOVIZ in Retina CareJuly 20, 2026 | quiverquant.comQHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingJuly 20, 2026 | globenewswire.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $49.00 at the beginning of the year. Since then, HROW stock has decreased by 23.2% and is now trading at $37.6470. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) released its quarterly earnings data on Monday, May, 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.31. The firm had revenue of $44.20 million for the quarter, compared to analysts' expectations of $52.43 million. Harrow had a negative net margin of 5.57% and a positive trailing twelve-month return on equity of 19.59%. Read the conference call transcript. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/11/2026Today7/28/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 As of 4 days ago, HROW's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees180Year Founded2012Price Target and Rating Average Price Target for Harrow$69.43 High Price Target$88.00 Low Price Target$63.00 Potential Upside/Downside+88.8%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E Ratio126.83 P/E GrowthN/ANet Income-$5.14 million Net Margins-5.57% Pretax Margin-4.16% Return on Equity19.59% Return on Assets2.26% Debt Debt-to-Equity Ratio10.30 Current Ratio2.48 Quick Ratio2.30 Sales & Book Value Annual Sales$268.68 million Price / Sales5.10 Cash Flow$0.83 per share Price / Cash Flow44.49 Book Value$1.41 per share Price / Book26.09Miscellaneous Outstanding Shares37,275,000Free Float32,504,000Market Cap$1.37 billion OptionableOptionable Beta0.26 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:HROW) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredA 50-year dollar arrangement just ended - what it means for youIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredElon Musk Set to Drop Bombshell on August 6One AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...InvestorPlace | SponsoredHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
